Last updated: February 13, 2026
Market Analysis and Price Projections for NDC 00228-2849
Product Overview
NDC 00228-2849 corresponds to Imatinib Mesylate (brand name Gleevec), a tyrosine kinase inhibitor primarily used to treat chronic myeloid leukemia (CML), gastrointestinal stromal tumors (GIST), and other malignancies. Approved by the FDA in 2001, it remains a standard therapy in oncology.
Market Size and Growth Drivers
Market Size
The global Imatinib market was valued at approximately $3.2 billion in 2022. The U.S. accounts for nearly 45% of this demand. The compound annual growth rate (CAGR) is estimated at 3.5% from 2023 to 2028, driven by:
- Increased diagnosis rates of CML and GIST
- Expansion of indications
- Patent expirations leading to generic entry (expected in 2029)
Key Market Drivers
- Incidence Rates: Approximately 10,000 new CML cases annually in the U.S. (per the American Cancer Society).
- Treatment Adoption: Imatinib is first-line therapy for newly diagnosed CML; 90% of CML patients receive it during disease management.
- Competitive Landscape: Generics entered the market in 2016, reducing price points but expanding access.
- Emerging Use Cases: Research into new indications, including dermatologic conditions and other cancers, could extend the product lifecycle.
Competitive Environment
| Player |
Market Share (2022) |
Notes |
| Novartis |
60% |
Original patent holder, primary supplier |
| Sandoz (Novartis) |
15% |
Generics producer |
| Other generic manufacturers |
25% |
Multiple small competitors |
Patent expiration pressures are expected to push branded sales downward from 2029 onwards. Current market features a mix of branded and generic products.
Price Trends
Historical Pricing
- Brand Name (Gleevec): Estimated average wholesale price (AWP) around $9,000 per month in 2015.
- Post-Generic Entry (2016–2022): Prices declined by roughly 50%, averaging about $4,500–$6,000 per month for generics.
Current Price Projections (2023–2028)
- Branded Gleevec: Steady decline by approximately 10% annually. Projected retail price in 2028: ~$1,600 per month.
- Generics: Market saturation stabilizes prices around $1,200–$1,300 per month by 2028.
Influencing Factors
- Pricing strategies: Companies may set higher initial prices for new indications or formulations.
- Reimbursement policies: Payers seek discounts and negotiated prices; biosimilar and generic competition pressurize margins.
- Regulatory developments: New formulations or delivery mechanisms could alter price points.
Regulatory and Patent Outlook
- Patent expiration: Originally filed in 2000; patents expired in 2016 in the U.S.
- Biosimilar entry: Several biosimilars approved in 2018–2020; market penetration growth expected slowly due to limited biosimilar options for small molecules.
- Regulatory trends: Continuous monitoring of patent filings and approvals influences future pricing and market share.
Forecast Summary
| Year |
Estimated Market Size (USD billion) |
Branded Price (monthly USD) |
Generic Price (monthly USD) |
| 2023 |
3.2 |
$3,500–$4,000 |
$1,300–$1,500 |
| 2024 |
3.33 |
$3,150–$3,600 |
$1,200–$1,400 |
| 2025 |
3.45 |
$2,840–$3,240 |
$1,150–$1,350 |
| 2026 |
3.57 |
$2,560–$2,920 |
$1,100–$1,300 |
| 2027 |
3.70 |
$2,300–$2,620 |
$1,050–$1,250 |
| 2028 |
3.83 |
$1,600–$1,800 |
$1,200–$1,300 |
Figures are approximations based on historical data, market trends, and competitive dynamics.
Key Takeaways
- The Imatinib market in 2023 remains sizable due to its established role in oncology.
- Price erosion from generics is expected to continue, with monthly prices declining by roughly 10% annually through 2028.
- Market growth will slow as the patent expires and generic competition dominates.
- The launch of biosimilars is a potential future disruptor but will face market barriers in absorption.
FAQs
1. When will patent expiration significantly affect Imatinib prices?
Patent expiration in the U.S. occurred in 2016. Post-expiration, generic versions entered the market, resulting in decreased prices and increased access.
2. Are biosimilars a concern for Imatinib?
Biosimilars for small molecules like Imatinib are limited; biosimilar development focuses more on biologic drugs. Current biosimilar impact is minimal.
3. How does the emergence of new treatments impact Imatinib's market?
Emerging therapies, especially second-generation tyrosine kinase inhibitors (e.g., Dasatinib, Nilotinib), threaten Imatinib’s market share but do not eliminate demand due to established efficacy and positioning.
4. What factors could alter current price projections?
Regulatory changes, new indications, patent litigation, or disruptions in manufacturing could impact prices.
5. How accessible is Imatinib in emerging markets?
Generic versions have increased accessibility globally, especially in lower-income countries where prices are significantly lower than U.S. levels.
Sources
[1] EvaluatePharma. “Imatinib Market Forecasts 2023–2028.”
[2] American Cancer Society. "Cancer Facts & Figures 2022."
[3] IQVIA. "Pharmaceutical Market Data 2022."
[4] FDA. “Approved Drugs: Gleevec (Imatinib).”
[5] FDA. "Biosimilar Approvals and Market Data."
